IQVIA (IQV) Expected to Post Quarterly Earnings on Tuesday

IQVIA (NYSE:IQV) is projected to release its Q2 2026 results before the market opens on Tuesday, July 28th. Analysts expect IQVIA to announce earnings of $3.02 per share and revenue of $4.3020 billion for the quarter. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, July 28, 2026 at 9:00 AM ET.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. During the same quarter last year, the business posted $2.70 earnings per share. IQVIA’s revenue for the quarter was up 8.4% compared to the same quarter last year. On average, analysts expect IQVIA to post $12 EPS for the current fiscal year and $13 EPS for the next fiscal year.

IQVIA Stock Performance

IQV stock opened at $204.33 on Tuesday. The company has a 50 day moving average price of $185.66 and a 200 day moving average price of $187.72. IQVIA has a fifty-two week low of $154.50 and a fifty-two week high of $247.04. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The stock has a market capitalization of $34.10 billion, a PE ratio of 25.32, a price-to-earnings-growth ratio of 1.85 and a beta of 1.20.

IQVIA announced that its board has approved a stock buyback plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board believes its shares are undervalued.

Hedge Funds Weigh In On IQVIA

Several hedge funds have recently added to or reduced their stakes in the stock. Quadrant Capital Group LLC boosted its holdings in IQVIA by 1.3% in the fourth quarter. Quadrant Capital Group LLC now owns 4,792 shares of the medical research company’s stock worth $1,080,000 after acquiring an additional 60 shares in the last quarter. Private Advisor Group LLC increased its holdings in shares of IQVIA by 1.0% during the third quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock valued at $1,163,000 after acquiring an additional 63 shares in the last quarter. Transamerica Financial Advisors LLC raised its position in shares of IQVIA by 16.7% in the 4th quarter. Transamerica Financial Advisors LLC now owns 495 shares of the medical research company’s stock valued at $112,000 after purchasing an additional 71 shares during the last quarter. E Fund Management Co. Ltd. raised its position in shares of IQVIA by 3.7% in the 2nd quarter. E Fund Management Co. Ltd. now owns 2,099 shares of the medical research company’s stock valued at $331,000 after purchasing an additional 74 shares during the last quarter. Finally, Ancora Advisors LLC boosted its stake in IQVIA by 17.9% in the 3rd quarter. Ancora Advisors LLC now owns 521 shares of the medical research company’s stock worth $99,000 after purchasing an additional 79 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on IQV. Evercore restated an “outperform” rating and set a $185.00 target price on shares of IQVIA in a research report on Wednesday, April 8th. HSBC reiterated a “buy” rating and issued a $240.00 price target on shares of IQVIA in a report on Monday, July 6th. Mizuho boosted their price objective on IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Morgan Stanley restated an “equal weight” rating and set a $200.00 target price (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 target price on shares of IQVIA in a research note on Thursday, July 9th. Fourteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $225.71.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.